RENT TEXTBOOKS

Section 1 Dermotology and Oncology
 
1 Epidemiology and Burden of Disease
Beth McLellan and Mario E. Lacouture

2 The History of Supportive Oncodermatology
Yevgeniy Balagula1, Steven T. Rosen and Mario E. Lacouture

3 Structure and Function of the Integumentary System and the Dermatology Lexicon
Emmy Garber and Amit Garg

4 Types of dermatologic reactions
Raed O. Alhusayen, Sandra R. Knowles and Neil H. Shear

5 Grading Dermatologic Adverse Events ... MOREon Clinical Trials using CTCAE v4.0
Alice Chen, Asha Acharya and Ann Setser

6 Psychosocial Issues in Oncology: Clinical management of psychosocial distress, health-related quality of life and special considerations in dermatologic oncology
Lynne I. Wagner and David Cella

7 Dermatopathology
James L. Troy and Molly Hinshaw

Section 2 
 
8 Cancer-Related Dermatologic Disorders
Cindy England Owen and Jeffrey P. Callen

Section 3 Dermatologic Conditions During Cancer Therapy 
 
9 ORAL MUCOSAL COMPLICATIONS OF CANCER THERAPY
Stephen T. Sonis

10 Hair Disorders Associated with Anticancer Agents
Caroline Yeager and Elise A. Olsen

11 NAIL ABNORMALITIES IN ONCOLOGY PRACTICE
Robert Baran, Bernard Fouilloux and Caroline Robert

12 Pruritus
Tejesh Patel and Gil Yosipovitch

13 Management Options for Hot Flashes in Cancer Patients
Amanda R. Moraska and Charles L. Loprinzi

Section 4 Skin toxicities due to chemotherapy 

14 Alkylating agents (Busulfan, ThioTEPA,  Mechlorethamine, Melphalan, Chlorambucil, cyclophosphamide, ifosfamide, carmustine, streptozocin, dacarbazine, temozolomide, etoposide,BCNU)
Elisabeth Livingstone, Lisa Zimmer, Larissa Schöttler, Dirk Schadendorf

15 Antimetabolite Reactions (Methotrexate, pemetrexed, capecitabine, cytarabine, gemcitabine, 6MP, 6-TG, fludarabine, cladribine)
Emily Y. Chu and Heidi H. Kong

16 Topoisomerase-interacting agents (irinotecan, topotecan, doxorubicin, daunorubicin,epirubicin, idarubicin, mitoxantrone, dactinomycin, etoposide, teniposide)
Tomas Skacel, Roger von Moos and Reinhard Dummer

17 Epidermal Growth Factor Receptor Inhibitor Reactions
Yevgeniy Balagula and Mario E. Lacouture

18 Small Molecule Kinase Inhibitors
Caroline Robert, Vincent Sibaud and Christine Mateus

19 Antimicrotubule agents (Paclitaxel, docetaxel, albumin-bound paclitaxel, vincristine, vinblastine, vi-norelbine, estramustine)
Claus Garbe

20 Histone Deacetylase Inhibitors (HDAC inhibitors) Proteasome inhibitors Demethylating Agents Arsenicals Retinoids
Najla Al-Dawsari, Shannon Campbell and Francine Foss

21 Miscellaneous Reactions (L-Asparaginase, bleomycin, thalidomide, lenalidomide)
Katharina C. Kaehler, Christine B. Boers-Doets, Mario E. Lacouture and Axel Hauschild

22 Skin toxicities due to biotherapy (Interferon-α2b, Interleukin-2)
Axel Hauschild, Katharina Kaehler and Mario Lacouture

23 Monoclonal antibodies
Caroline Robert

24 Endocrine Agents
Katherine Szyfelbein and Mario Lacouture

25 Agents for the management of hematologic reactions: epotein alpha, darbopoetin, G-CSF, GM-CSF; oprelvekin; low molecular weight heparin; warfarin.
Mee-young Lee  and Caroline C. Kim

26 RDERMATOLOGICAL PRINCIPLES AND PRACTICE IN ONCOLOGY 
Rebecca Wong and Zahra Kassam

27 Hematopoietic stem cell transplantation and graft-versus-host disease 
Stephanie Hu and Jonathan Cotliar

28 Extravasation Reactions
Seppo  W. Langer

29 Topical Anticancer Therapies
Patricia  L. Myskowski

30 Life-threatening (Serious) Dermatologic Adverse Events
Milan Anadkat

31 Dermatologic infections
Yevgeniy Balagula, Mario E. Lacouture and James I. Ito

Section 5   

32 Late Dermatologic Conditions
Jennifer Namchoi

Section 6 Dermatologic Practice in Oncology 

33 Management Algorithms for Dermatologic Adverse Events
Alyx Rosen, Iris Amitay-Laish and Mario E. Lacouture

34 Dermatological therapeutics and formulations
Judy H. Borovicka, Jennifer RS Gordon, Ann Cameron Haley and Dennis P. West

35 Dermatological Techniques and Procedures
Kishwer Nehal, Erica Lee and Robert Eilers

36 Appearance-Related Concerns in the Cancer Patient
Amy J. Derick